AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update • Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau and a-syn • Cash resources of CHF 108.5 million as of ...

ACIU

<p>AC Immune 發佈 2025 年第三季度財務報告並提供公司更新 • 加強對高價值資產的投資關注，包括三個處於第二階段的活性免疫療法項目和針對 NLRP3、Tau 和α-syn 的小分子項目 • 截至...現金資源為 1.085 億瑞士法郎</p>

AC Immune 公佈 2025 年第三季度財務業績並提供公司最新動態